Signature Wealth Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Signature Wealth Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$235K	Sell	527 -3,797	-88%	-$1.77M	0.09%	122
2025 Q4	$1.96M	Buy	4,324 +213	+5%	+$91.8K	0.8%	49
2025 Q3	$1.61M	Sell	4,111 -133	-3%	-$55.6K	0.62%	56
2025 Q2	$1.89M	Buy	4,244 +26	+0.6%	+$12K	0.75%	56
2025 Q1	$2.04M	Buy	4,218 +143	+4%	+$66.6K	0.8%	49
2024 Q4	$1.64M	Buy	4,075 +103	+3%	+$47.7K	0.66%	59
2024 Q3	$1.85M	Buy	3,972 +215	+6%	+$103K	0.74%	49
2024 Q2	$1.76M	Buy	3,757 +2,116	+129%	+$918K	0.77%	53
2024 Q1	$647K	Buy	+1,641	New	+$694K	0.29%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Signature Wealth Management Group's VRTX Position: Q1 2026 in Review

Signature Wealth Management Group reduced its Vertex Pharmaceuticals (VRTX) stake by 88% in Q1 2026, selling an estimated $1.77M and leaving 527 shares worth $235K. The position accounts for 0.09% of the portfolio, ranked #122.

Signature Wealth Management Group first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.04M in Q1 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Signature Wealth Management Group held 527 shares of Vertex Pharmaceuticals worth $235K as of Q1 2026.
Signature Wealth Management Group sold 3,797 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.77M.
Vertex Pharmaceuticals made up 0.09% of Signature Wealth Management Group's portfolio in Q1 2026, its #122 holding.
Signature Wealth Management Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Signature Wealth Management Group's Vertex Pharmaceuticals position peaked at $2.04M in Q1 2025.
1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Signature Wealth Management Group's 13F filing for Q1 2026, filed 1 Apr 2026.